

OncoTherapy Science, Inc.

September 4, 2015

The termination of the agreement with Shionogi & Co., Ltd.
on the peptide vaccine for disease in ophthalmic field.

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that OncoTherapy received the notification of termination of the licensing agreement on development, manufacturing and distribution of the peptide vaccine derived from vascular endothelial growth factor receptors for the disease caused by the vascular proliferation in retina such as age-related macular degeneration from Shionogi & Co., Ltd. (Head office:Chuo-ku, Osaka, President and CEO: Isao Teshirogi, hereinafter “Shionogi”). This termination is due to the corporate strategies of Shionogi that development of its peptide vaccines is focusing on cancer field.

OncoTherapy will facilitate the strategic dialogues with our licensing-out partners, and enforce the indirect and logistic supports for clinical developments conducted by these partners. OncoTherapy has gained the agreement with Shionogi on the supports for Phase III clinical trial of the cancer-specific peptide vaccine S-588410 for esophageal cancer, which has been conducted by Shionogi. In addition, Shionogi has been conducting Phase II clinical trial of S-588410 for bladder cancer in Japan, Europe and Phase I/II clinical trial of S-488210 in head and neck cancer in Europe.